9.27.2007
The IN VIVO Blog: PSA Day 2: Buying into Biologics
The IN VIVO Blog: PSA Day 2: Buying into Biologics: "Building biologics expertise and capabilities piecemeal, says Mott, will be a long, slow and high-risk proposition, thanks in part to the dearth of biologics industry talent in key areas like regulatory affairs."
